TD Cowen analyst Phil Nadeau maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) today. The company’s shares opened ...

TD Cowen analyst Andrew Kligerman maintained a Buy rating on Abacus Life (ABL – Research Report) today and set a price target of $14.00. The ...

El Lilly’s blockbuster weight-loss drug Zepbound is now eligible for coverage under Medicare prescription drug plans, when ...

Fintel reports that on January 8, 2025, TD Cowen upgraded their outlook for Sana Biotechnology (NasdaqGS:SANA) from Hold to ...

The cost of prescription drugs is set to climb in 2025 and beyond, according to TD Cowen’s 30th Annual Drug Pricing survey.

Lisa Thomas, Managing Director and Deputy Head of Global Research at TD Cowen, discusses some of the key findings of a new TD Cowen report on the big investment themes of 2025, including shifting ...

Fintel reports that on January 8, 2025, TD Cowen downgraded their outlook for J. M. Smucker (NYSE:SJM) from Buy to Hold.

“Two-thousand-twenty-four was a tough year for staples stocks, and 2025 is shaping up to be even tougher,” says TD Cowen ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

Shares of American Airlines surged Monday after brokerages Jefferies and TD Cowen upgraded and raised their price targets on ...

American Airlines' stock is poised for a strong 2025 as the carrier emerges from a challenging year, according to brokerages ...

TD Cowen analyst Jeff Osborne initiated coverage of Nextracker (NXT) with a Hold rating and $41 price target The firm likes the company’s management team, portfolio and market presence and sees ...